Does Blue Cross Blue Shield Cover Weight Loss Drugs? Honest Coverage Review

Short version: there is no single answer because “Blue Cross Blue Shield” is not one company. It is a federation of roughly 33 independent, locally operated licensees — Anthem/Elevance, Florida Blue, Blue Cross Blue Shield of Michigan, Highmark, Horizon, CareFirst, BCBS of Texas, BCBS of Massachusetts, and dozens more — plus the national Federal Employee Program (FEP).^[1] Each local Blue plan sets its own formulary, prior-authorization rules, and AOM (anti-obesity-medication) benefit decisions. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus) are widely covered across Blue plans with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are covered on many Blue plans with PA + BMI criteria — but many employer groups carve them out entirely, and several Blue plans have dropped them altogether (BCBS of Michigan for fully insured large groups in 2025; BCBS of Massachusetts and Blue Cross Vermont as benefit exclusions starting January 1, 2026).^[7][13][14] Medicare is its own track: Part D still excludes weight-loss drugs, but since July 1, 2026 the CMS Medicare GLP-1 Bridge offers eligible Part D enrollees — including BCBS Medicare plan members — Wegovy, Zepbound KwikPen, or Foundayo for a $50 copay.^[15]

At a glance

• BCBS is a federation, not one insurer. Roughly 33 independent, locally operated Blue Cross and/or Blue Shield companies cover about 118 million members across all 50 states, DC, and Puerto Rico. Each is a separate legal entity with its own formulary, PA rules, and benefit designs.^[1] There is NO single national BCBS formulary for weight-loss drugs.
• Type 2 diabetes GLP-1s: generally YES with PA across most Blue plans. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus are commonly on-formulary for the diabetes indication.
• Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): VARIES by plan and employer group. Many Blue plans cover them with PA + BMI criteria; many employer groups carve AOMs out; several Blue plans dropped weight-loss GLP-1 coverage outright — Blue Cross Blue Shield of Michigan for fully-insured large-group commercial members (effective 01/01/2025), and Blue Cross Blue Shield of Massachusetts and Blue Cross Vermont as pharmacy-benefit exclusions starting 01/01/2026.^[7][13][14]
• The FEP anchor (federal employees): the BCBS Service Benefit Plan publishes uniform 2026 weight-loss criteria. Wegovy/Saxenda criteria live in FEP policy 5.99.030 (effective 02/13/2026); Zepbound in policy 5.99.031 (effective 01/01/2026). Both require BMI ≥30, OR ≥27 with a weight-related comorbidity, age 12+ (Wegovy/Saxenda injection) or 18+ (Wegovy tablets, Zepbound), a comprehensive weight-management program, and — for continuation — documented ≥5% weight loss reassessed at 12-16 weeks.^[2][3] On the 2026 FEP formulary, Wegovy and Saxenda are Tier 3 with prior approval on FEP Blue Standard and Basic but not covered on FEP Blue Focus, and Zepbound sits on the Standard excluded-drug and Basic “managed not covered” lists.^[4]
• BCBS Medicare Advantage (Part D): the plan itself still cannot cover weight-loss-only Wegovy/Zepbound/Saxenda — federal Part D excludes “agents when used for ... weight loss or weight gain.”^[5] It can cover the non-weight-loss indications: Zepbound for obstructive sleep apnea, and Wegovy for cardiovascular risk reduction or MASH.^[6][9][10] Separately, the CMS Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) runs outside the Part D benefit and gives eligible Part D enrollees Wegovy, Zepbound KwikPen, or Foundayo for weight loss at a $50 copay.^[15][16]
• PBM varies by plan. Different Blue companies route prescriptions through different pharmacy-benefit managers — many use CVS Caremark (which administers the FEP pharmacy benefit), others Express Scripts, Prime Therapeutics, or Elevance's CarelonRx. The PA portal and preferred-product designations follow the PBM, not a single Blue rulebook.^[8]
• Cost when covered: typical Blue copay tiers place GLP-1s on a preferred or non-preferred brand tier; out-of-pocket after PA approval is generally $25-$100+/month depending on plan and tier.

Why “does Blue Cross cover weight-loss drugs” has no single answer

Most national payers — Aetna, UnitedHealthcare, Cigna — are a single company with one corporate formulary. Blue Cross Blue Shield is structurally different: it is a federation. The Blue Cross Blue Shield Association licenses the Blue Cross and Blue Shield trademarks to roughly 33 independent, locally operated companies, each holding an exclusive geographic territory.^[1]

Familiar names that are all separate Blue licensees include:

• Anthem / Elevance Health — Blue plans across 14 states (CA, NY, GA, OH, IN, KY, VA, CO, CT, ME, MO, NH, NV, WI), using CarelonRx as its PBM.
• Florida Blue (Blue Cross and Blue Shield of Florida).
• Blue Cross Blue Shield of Michigan — which dropped weight-loss GLP-1 coverage for fully-insured large-group commercial members effective 01/01/2025.^[7]
• Highmark (PA, WV, DE, NY).
• Horizon Blue Cross Blue Shield of New Jersey.
• CareFirst BlueCross BlueShield (MD, DC, Northern VA).
• Health Care Service Corporation (HCSC) — operating BCBS of Illinois, Texas, Oklahoma, New Mexico, and Montana.
• Blue Cross Blue Shield of Massachusetts — which excluded GLP-1s for obesity (Wegovy, Zepbound, Saxenda) from its pharmacy benefit starting January 1, 2026 and at each group's 2026 renewal, unless the employer buys a rider.^[13]

Three practical consequences for weight-loss-drug coverage:

1. Each Blue plan sets its own formulary and PA rules. A drug covered with PA on Florida Blue commercial may be excluded on a BCBS Michigan large-group plan, or placed on a different tier on Anthem. There is no national BCBS weight-loss formulary you can look up once.
2. The employer group matters as much as the plan. Most Blue commercial coverage is employer-sponsored. The employer chooses whether the benefit includes AOMs. The same Florida Blue plan name can include or exclude Wegovy/Zepbound depending entirely on the group's benefit design — which is why “I have Blue Cross” tells you almost nothing.
3. The PBM varies. The pharmacy-benefit manager adjudicating your PA — CVS Caremark, Express Scripts, Prime Therapeutics, or CarelonRx — depends on your specific Blue plan. The PA portal, preferred-product list, and step-therapy rules follow that PBM.^[8]

The most national anchor: BCBS Federal Employee Program (FEP)

Because the local Blue plans are so heterogeneous, the closest thing to a “national BCBS” weight-loss policy is the Federal Employee Program (FEP) — the Blue Cross and Blue Shield Service Benefit Plan available to federal employees, retirees, and their families in every region where a Blue plan operates. FEP publishes uniform clinical criteria nationally, and its pharmacy benefit is administered by CVS Caremark.^[8] FEP offers three plan types: FEP Blue Standard, FEP Blue Basic, and FEP Blue Focus.

FEP's 2026 weight-loss-medication criteria are spelled out in two published policies:

• Saxenda / Wegovy — FEP policy 5.99.030, effective February 13, 2026 (last reviewed December 12, 2025). It now covers Wegovy injection, the newer Wegovy tablets (adults 18+), and a separate Wegovy-injection pathway for MASH.^[2]
• Zepbound — FEP policy 5.99.031, effective January 1, 2026 (last reviewed December 12, 2025).^[3]

FEP 2026 prior-approval criteria for Wegovy/Saxenda (chronic weight management), verbatim from policy 5.99.030: age 12+; for adults (18+) a BMI ≥30 kg/m², OR BMI ≥27 kg/m² with established cardiovascular disease OR at least one weight-related comorbid condition (type 2 diabetes, dyslipidemia, or hypertension); patient has participated in a comprehensive weight-management program (e.g., Teladoc or another weight-loss program); no dual therapy with another GLP-1; and for ages 12-17, BMI ≥95th percentile for age. Wegovy tablets follow the same adult criteria (18+ only). The policy also has a non-weight-loss MASH pathway for Wegovy injection: adults 18+ with moderate-to-advanced fibrosis (F2-F3) confirmed by biopsy or imaging, no cirrhosis, prescribed by or with an endocrinologist, gastroenterologist, or hepatologist.^[2][10]

FEP 2026 prior-approval criteria for Zepbound, from policy 5.99.031: age 18+; chronic weight management with BMI ≥30, OR BMI ≥27 with established CVD or a weight-related comorbidity; an inadequate response, intolerance, or contraindication to at least two oral weight-management drugs (e.g., phentermine, Qsymia); a trial of the preferred product(s) unless there is a valid medical exception; and participation in a comprehensive weight-management program. The policy lists Zepbound's OSA indication in its regulatory background, but its prior-approval criteria are written for chronic weight management only.^[3][6]

FEP continuation/reauthorization (both policies): evaluate the decrease in BMI after 12-16 weeks of treatment; for continued adult approval the patient must have lost — or continued to maintain — at least 5% of baseline body weight, plus ongoing participation in the comprehensive weight-management program. Per the policies' revision history, FEP added the behavior-modification requirement for initiation and the 5% continuation threshold in its December 2024 review, and both remain in the 2026 versions.^[2][3]

Important FEP nuance: the three FEP plan types differ on coverage and tier. In the 2026 FEP abbreviated formulary, Wegovy and Saxenda are Tier 3 (prior approval) on FEP Blue Standard and FEP Blue Basic but marked “NC” (not covered) on FEP Blue Focus. Zepbound appears on the FEP Blue Standard excluded-drug list and the FEP Blue Basic “managed not covered” list, with Wegovy, Saxenda, generic liraglutide, and oral agents named as the covered alternatives.^[4] In practice, Wegovy is the default FEP GLP-1 for weight loss, and Zepbound needs an exception. Confirm your exact plan type and current tier at fepblue.org before assuming coverage.

Local Blue plans: a wide spectrum (covers vs carves out)

Outside FEP, each local Blue plan lands somewhere on a spectrum from generous AOM coverage to a full carve-out. Two illustrative anchors:

• Covers with PA. Many Blue plans — where the employer group includes the AOM benefit — cover Wegovy and/or Zepbound for chronic weight management with prior authorization. The PA pattern tracks FDA labeling: BMI ≥30, OR BMI ≥27 with a comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — for Zepbound — moderate-to-severe OSA), plus documented lifestyle/behavioral intervention, sometimes with a step-therapy or 6-month diet-and-exercise requirement.
• Carves out or dropped entirely. Blue Cross Blue Shield of Michigan ended coverage of GLP-1 weight-loss drugs (Wegovy, Zepbound, Saxenda) for fully-insured large-group commercial members effective January 1, 2025; self-funded employer plans administered by BCBSM may still choose to cover, so members must check with HR.^[7] Blue Cross Blue Shield of Massachusetts made GLP-1s for obesity a pharmacy-benefit exclusion starting January 1, 2026 (and at each 2026 renewal); it says exceptions and appeals are not available because the drugs are benefit-excluded, and the only route is an employer-purchased rider.^[13] Blue Cross Vermont did the same from January 1, 2026 for Wegovy, Zepbound, and Saxenda.^[14] More broadly, a large share of employer groups across all Blue plans carve AOMs out of the pharmacy benefit to control premium cost.

One more wrinkle: when a plan excludes weight-loss drugs, the non-weight-loss indications do not always survive. BlueCross BlueShield of South Carolina, for example, said that from August 1, 2026, commercial plans without weight-loss coverage may still cover Wegovy for cardiovascular risk reduction or MASH with prior authorization — but Zepbound for sleep apnea “will not be reviewed for medical necessity” on those plans.^[17] The takeaway: the local-plan answer is genuinely bimodal. You cannot infer it from the “Blue Cross” brand — you have to check your specific plan's formulary and your employer group's benefit summary. For the underlying weight-loss magnitudes that anchor every Blue plan's PA criteria, see our semaglutide drug page and tirzepatide drug page.

BCBS Medicare Advantage (Part D) — federal exclusion

Many Blue plans sell Medicare Advantage prescription-drug (MA-PD) products. Like every Medicare Part D plan in the country, they operate under Social Security Act §1860D-2(e)(2)(A), which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[5] This is a federal statutory exclusion — a BCBS Medicare Advantage plan cannot cover Wegovy, Zepbound, or Saxenda for a weight-loss-only indication regardless of medical-necessity documentation.

Three carve-ins where a BCBS Medicare Advantage plan CAN cover an otherwise-excluded GLP-1, because the indication is not weight loss:

• Zepbound for moderate-to-severe obstructive sleep apnea. FDA approved this distinct indication on December 20, 2024. Because OSA is not a weight-loss indication, the Part D exclusion does not apply, and some BCBS MA formularies now cover Zepbound for OSA in adults with obesity subject to PA. The SURMOUNT-OSA trial is the underlying evidence base.^[6][9] Coverage still varies plan-by-plan — confirm on your specific BCBS MA formulary.
• Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication is reducing the risk of major adverse cardiovascular events in adults with established CVD plus overweight/obesity (per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b^[10]). As a non-weight-loss indication, this is coverable on Part D — though individual BCBS MA formularies vary on how aggressively they cover it. Type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity) are also unaffected by the weight-loss exclusion.
• Wegovy for MASH. Wegovy injection is also FDA-approved (under accelerated approval) for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced (F2-F3) fibrosis in adults.^[10] CMS lists MASH, along with type 2 diabetes and moderate-to-severe OSA, as indications that remain eligible for regular Part D coverage.^[16]

The Medicare GLP-1 Bridge (new in 2026). For weight loss itself, the change is a CMS demonstration rather than a Part D formulary decision. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge gives eligible Part D enrollees access to Wegovy (injection and tablets), Zepbound KwikPen, and Foundayo for a $50 copay. It runs outside the Part D benefit: Part D plans do not have to opt in, a single CMS processor handles prior authorization and claims, the Part D deductible does not apply, and the $50 does not count toward out-of-pocket totals.^[15] Eligibility starts at BMI ≥35; BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or stage 3a+ chronic kidney disease; or BMI ≥27 with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.^[16] Because it sits outside the plan, a BCBS Medicare Advantage or Part D member does not need the Blue plan to cover the drug. Check eligibility at Medicare.gov/glp1bridge or 1-800-MEDICARE.

How to find out if YOUR Blue Cross plan covers Wegovy or Zepbound

Because the answer is plan- and employer-specific, go straight to the authoritative sources, in order:

1. Find out which Blue plan you actually have. The card identifies the local licensee (e.g., “Florida Blue,” “Anthem Blue Cross,” “BCBS of Michigan,” “BCBS FEP”). That determines the formulary and PBM you're subject to. FEP cards say “Service Benefit Plan” with an enrollee ID beginning with R.
2. Search your plan's online formulary / drug list. Sign in to your local Blue plan's member portal (or fepblue.org for FEP), open the prescription drug list, and search “Wegovy” or “Zepbound.” The result shows the tier and whether prior authorization or step therapy applies. FEP enrollees can also review policies 5.99.030 and 5.99.031.^[2][3]
3. Confirm your employer group includes the AOM benefit. Even if the plan's formulary lists Wegovy/Zepbound, your specific employer group may have carved AOMs out. Ask HR or your benefits administrator for the Summary of Benefits and Coverage (SBC) and the excluded-drugs list. This is the step most people skip — and it's where many denials originate.
4. Call the member-services number on your card. Ask specifically: “Does my plan and group cover [drug name] for chronic weight management? What is the copay tier, the PA requirement, and is there a step-therapy or behavioral-program requirement?”

Prior authorization at a Blue plan

Unlike an integrated HMO such as Kaiser Permanente, most Blue plans are PBM-administered, so the PA flow runs through the plan's PBM rather than an internal committee. The typical flow:

1. Your prescriber documents that you meet the plan's criteria — for most Blue plans and for FEP, that is BMI ≥30 (or ≥27 with a weight-related comorbidity), adult age (FEP allows 12+ for Wegovy/Saxenda injection), and participation in a comprehensive weight-management/behavioral program.^[2][3]
2. The prescriber submits the PA request through the plan's PBM portal (CVS Caremark for FEP; CarelonRx, Express Scripts, or Prime Therapeutics for various local Blue plans).^[8]
3. The PBM adjudicates against the plan's published criteria. Turnaround varies by plan and PBM, typically a few business days for a standard request.
4. Continuation requires response. For FEP, BMI is reassessed at 12-16 weeks and continued coverage requires documented ≥5% weight loss from baseline plus ongoing program participation; many local Blue plans apply similar response requirements.^[2][3]

If denied: the appeal pathway (varies by plan and state)

The appeal pathway depends on whether your plan is fully insured (state-regulated) or a self-funded employer plan (ERISA/federal), and on your state. The general shape:

1. Internal appeal with your Blue plan, within the timeframe on the denial notice (commonly 180 days for commercial). The member or prescriber submits a written appeal with additional clinical documentation. FEP members appeal through FEP's defined process and can ultimately ask OPM to review.^[8]
2. Second-level internal review where the plan offers one.
3. External review. For a fully-insured state-regulated Blue plan, an independent external review (IRO) is available through your state insurance department or department of managed care; the IRO decision is binding on the plan. For an ERISA self-funded employer plan administered by a Blue company, appeals follow ERISA's federal framework rather than the state IRO.
4. FEP-specific track. FEP is a federal program — disputes can ultimately be reviewed by the U.S. Office of Personnel Management (OPM), which administers the FEHB program.^[8]

For the operational playbook on appealing dropped or denied coverage across any payer including Blue plans, see our insurance coverage hub. To compare provider options if you decide to pursue treatment outside your plan, see our best semaglutide providers and best tirzepatide providers rankings.

If your Blue plan denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Confirm it's a true exclusion, not a fixable PA denial. Many initial denials are missing the comprehensive-weight-management-program documentation or the comorbidity attestation. Re-submitting with complete documentation against the plan's exact criteria resolves a large share of denials before you ever pay cash.
• The Zepbound OSA pathway. If you have a moderate-to-severe OSA diagnosis (AHI ≥15), your prescriber can submit a Zepbound PA for the OSA indication, not weight loss — relevant for BCBS Medicare Advantage (Part D exclusion does not apply). On commercial plans that exclude weight-loss drugs, check first: some Blue plans (e.g., BCBS of South Carolina) do not review Zepbound-for-OSA requests on those plans.^[6][9][17]
• Wegovy for cardiovascular risk reduction. If you have established CVD plus overweight/obesity, your prescriber can submit a Wegovy PA for the CV-risk-reduction indication — a separate FDA-approved, non-weight-loss indication. If you have biopsy- or imaging-confirmed MASH with F2-F3 fibrosis, Wegovy injection's MASH indication is another non-weight-loss route.^[10][17]
• On Medicare? Check the Medicare GLP-1 Bridge. Through December 31, 2027, eligible Part D enrollees can get Wegovy, Zepbound KwikPen, or Foundayo for weight loss at a $50 copay, outside the Blue plan's formulary.^[15][16]
• Lilly self-pay Zepbound. Lilly lists the regular self-pay price of the Zepbound KwikPen at $299/month (2.5 mg), $399 (5 mg), $499 (7.5 mg), and $699 (10/12.5/15 mg), with a purchase offer that can bring 7.5-15 mg down to as low as $449/month (terms apply) — cash-pay, no insurance involvement. Useful if your group permanently carves AOMs out.^[18]
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically $149-$349/month. Not FDA-approved and not brand Wegovy or Zepbound. FDA declared both shortages resolved (semaglutide in February 2025), and it says compounders may not regularly make “essentially copies” of commercially available drugs, so legitimate compounded products now need a documented patient-specific change. Quality and supply-chain rigor vary widely, so diligence matters.^[19]
• Switch plans or groups at open enrollment. If your specific Blue group permanently excludes AOMs, the realistic option is the next open-enrollment window — choosing a plan or group whose formulary includes Wegovy/Zepbound. Because Blue is a federation, even moving between Blue plans can change the answer entirely.

For mechanism-of-action context and the underlying weight-loss magnitudes (STEP-1 semaglutide -14.9% body weight at 68 weeks^[11]; SURMOUNT-1 tirzepatide 15 mg -20.9% at 72 weeks^[12]), see our semaglutide and tirzepatide drug pages.

Verdict — what most Blue Cross members should expect

For the median Blue Cross Blue Shield member asking does Blue Cross cover weight-loss drugs, there is no single national yes-or-no, because Blue Cross is a federation of independent companies. The answer splits by plan, by employer group, and by indication:

1. Type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES with PA across most Blue plans.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda) on a commercial Blue plan: DEPENDS on your specific local plan AND whether your employer group includes the AOM benefit. Many cover with PA + BMI criteria; many groups carve out; some plans dropped them outright (BCBS Michigan large-group fully insured in 2025; BCBS Massachusetts and Blue Cross Vermont in 2026).^[7][13][14]
3. FEP (federal employees): uniform 2026 criteria — BMI ≥30 (or ≥27 with comorbidity), age 12+ (Wegovy/Saxenda injection) or 18+ (Wegovy tablets, Zepbound), comprehensive weight-management program, ≥5% weight loss for continuation. On the 2026 formulary Wegovy is covered with prior approval on Standard and Basic but not on Blue Focus, and Zepbound needs an exception.^[2][3][4]
4. BCBS Medicare Advantage members: the plan still cannot cover weight-loss-only use; it can cover Zepbound for OSA and Wegovy for CV risk reduction or MASH, subject to plan formulary. For weight loss itself, the CMS Medicare GLP-1 Bridge offers a $50 copay to eligible enrollees through 2027.^{[5][6][10][15]}

The single most useful thing you can do is identify your exact local Blue plan and confirm with HR whether your employer group includes the anti-obesity-medication benefit — that one question resolves most of the uncertainty before you ever start a prior authorization.

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• GLP-1 insurance coverage hub